Limits...
The effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment.

Zhou T, Zheng L, Hu Z, Zhang Y, Fang W, Zhao Y, Ge J, Zhao H, Zhang L - Sci Rep (2015)

Bottom Line: In the combination therapy group, patients with PR or SD had longer overall survival (OS) than those with PD (P < 0.001 and P = 0.002, respectively).However, in the chemotherapy alone group, compared with PD patients, either PR or SD group had no significant overall survival benefit (P = 0.690 and P = 0.528, respectively).In summary, for advanced NSCLC patients receiving chemotherapy plus target therapy as first-line treatment and evaluated by RECIST criteria, SD has the same overall survival benefit as PR, suggesting that antitumor effective evaluation by RECIST criteria cannot be translated to overall survival benefit especially for this kind of patients.

View Article: PubMed Central - PubMed

Affiliation: 1] Sun-Yat Sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou 510060, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou 510060, China.

ABSTRACT
We analyzed the correlation between survival and antitumor effect evaluated by RECIST in advanced NSCLC patients with chemotherapy plus target therapy or not as first-line treatment, to examine the applicability of RECIST in this population. The patients were screened from 4 clinical trials (12621, 12006, FASTACT-I, and FASTACT-II), and those who received chemotherapy plus target therapy or chemotherapy alone were eligible. Among the 59 enrolled patients, 29 received combination therapy, while the other 30 received chemotherapy only. In the combination therapy group, patients with PR or SD had longer overall survival (OS) than those with PD (P < 0.001 and P = 0.002, respectively). However, in the chemotherapy alone group, compared with PD patients, either PR or SD group had no significant overall survival benefit (P = 0.690 and P = 0.528, respectively). In summary, for advanced NSCLC patients receiving chemotherapy plus target therapy as first-line treatment and evaluated by RECIST criteria, SD has the same overall survival benefit as PR, suggesting that antitumor effective evaluation by RECIST criteria cannot be translated to overall survival benefit especially for this kind of patients. Therefore, developing a more comprehensive evaluation method to perfect RECIST criteria is thus warranted for patients received target therapy in NSCLC.

No MeSH data available.


Related in: MedlinePlus

PFS and OS curves for the 59 patients with different response after therapy: (A) Comparison of PFS among patients with PR, SD, and PD. (B) Comparison of OS among patients with PR, SD, and PD.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4286759&req=5

f3: PFS and OS curves for the 59 patients with different response after therapy: (A) Comparison of PFS among patients with PR, SD, and PD. (B) Comparison of OS among patients with PR, SD, and PD.

Mentions: The correlation between the response to therapy and the survival was examined using univariate analysis. The median survival time of PR, SD, and PD groups was 27.8, 24.1, and 10.6 months, respectively, while the corresponding median PFS was 7.4, 6.9, and 1.5 months, respectively. Of the 59 evaluated patients, comparing with PD patients, the ones with disease control (PR + SD) showed obvious survival benefit (P = 0.001) (Table 4). In further comparison, the PFS of both PR and SD groups were significantly longer than that of the PD group (both P < 0.001). The PR and SD groups also showed a longer survival time compared with PD group (P = 0.002 and P = 0.018, respectively. There were no significant difference in OS (P = 0.847) and PFS (P = 0.747) observed between PR and SD groups (Figure 3).


The effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment.

Zhou T, Zheng L, Hu Z, Zhang Y, Fang W, Zhao Y, Ge J, Zhao H, Zhang L - Sci Rep (2015)

PFS and OS curves for the 59 patients with different response after therapy: (A) Comparison of PFS among patients with PR, SD, and PD. (B) Comparison of OS among patients with PR, SD, and PD.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4286759&req=5

f3: PFS and OS curves for the 59 patients with different response after therapy: (A) Comparison of PFS among patients with PR, SD, and PD. (B) Comparison of OS among patients with PR, SD, and PD.
Mentions: The correlation between the response to therapy and the survival was examined using univariate analysis. The median survival time of PR, SD, and PD groups was 27.8, 24.1, and 10.6 months, respectively, while the corresponding median PFS was 7.4, 6.9, and 1.5 months, respectively. Of the 59 evaluated patients, comparing with PD patients, the ones with disease control (PR + SD) showed obvious survival benefit (P = 0.001) (Table 4). In further comparison, the PFS of both PR and SD groups were significantly longer than that of the PD group (both P < 0.001). The PR and SD groups also showed a longer survival time compared with PD group (P = 0.002 and P = 0.018, respectively. There were no significant difference in OS (P = 0.847) and PFS (P = 0.747) observed between PR and SD groups (Figure 3).

Bottom Line: In the combination therapy group, patients with PR or SD had longer overall survival (OS) than those with PD (P < 0.001 and P = 0.002, respectively).However, in the chemotherapy alone group, compared with PD patients, either PR or SD group had no significant overall survival benefit (P = 0.690 and P = 0.528, respectively).In summary, for advanced NSCLC patients receiving chemotherapy plus target therapy as first-line treatment and evaluated by RECIST criteria, SD has the same overall survival benefit as PR, suggesting that antitumor effective evaluation by RECIST criteria cannot be translated to overall survival benefit especially for this kind of patients.

View Article: PubMed Central - PubMed

Affiliation: 1] Sun-Yat Sen University Cancer Center, Guangzhou, China [2] State Key Laboratory of Oncology in South China, Guangzhou 510060, China [3] Collaborative innovation Center for Cancer Medicine, Guangzhou 510060, China.

ABSTRACT
We analyzed the correlation between survival and antitumor effect evaluated by RECIST in advanced NSCLC patients with chemotherapy plus target therapy or not as first-line treatment, to examine the applicability of RECIST in this population. The patients were screened from 4 clinical trials (12621, 12006, FASTACT-I, and FASTACT-II), and those who received chemotherapy plus target therapy or chemotherapy alone were eligible. Among the 59 enrolled patients, 29 received combination therapy, while the other 30 received chemotherapy only. In the combination therapy group, patients with PR or SD had longer overall survival (OS) than those with PD (P < 0.001 and P = 0.002, respectively). However, in the chemotherapy alone group, compared with PD patients, either PR or SD group had no significant overall survival benefit (P = 0.690 and P = 0.528, respectively). In summary, for advanced NSCLC patients receiving chemotherapy plus target therapy as first-line treatment and evaluated by RECIST criteria, SD has the same overall survival benefit as PR, suggesting that antitumor effective evaluation by RECIST criteria cannot be translated to overall survival benefit especially for this kind of patients. Therefore, developing a more comprehensive evaluation method to perfect RECIST criteria is thus warranted for patients received target therapy in NSCLC.

No MeSH data available.


Related in: MedlinePlus